Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesKinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in head and neck cancer patients before and early after initiation of chemoradiation therapy
The Journal of Nuclear Medicine, 06/16/09
Menda Y et al. - In a study to investigate the kinetic behavior of 3'-deoxy-3'-18F-fluorothymidine (18F-FLT) before and early after initiation of chemoradiation therapy in pts with squamous cell head and neck cancer (SCHNC), it was found that the initial 18F-FLT uptake and change early after treatment in SCHNC can be adequately characterized with standardized uptake value (SUV) obtained at 45–60 min, which demonstrates excellent correlation with influx parameters obtained from compartmental and Patlak analyses.
Methods- 8 pts with head and neck cancer underwent 18F-FLT PET scans (7 pts at baseline and after 5 d [10 Gy] of radiation therapy given with concomitant chemotherapy and 1 pt only at baseline).
- Dynamic PET images were obtained with concurrent arterial or venous blood sampling.
- Kinetic parameters including the flux constant of 18F-FLT based on compartmental analysis (K-FLT), the Patlak influx constant (K-Patlak), and SUV were calculated for the primary tumor and 18F-FLT–avid cervical lymph nodes for all scans.
- Mean pretreatment values of uptake for the primary tumor and cervical nodes were 0.075 ± 0.006 min-1, 0.042 ± 0.004 min-1, and 3.4 ± 0.5 (mean ± SD) for K-FLT, K-Patlak, and SUV, respectively.
- After 10 Gy of radiation therapy, these values were 0.040 ± 0.01 min-1, 0.018 ± 0.016 min-1, and 1.8 ± 1.1 for K-FLT, K-Patlak, and SUV, respectively.
- For all lesions seen on pretherapy and midtherapy scans, the correlation was 0.90 between K-FLT and K-Patlak, 0.91 between K-FLT and SUV, and 0.99 between K-Patlak and SUV.
Today in Nuclear Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Breast Cancer: Role of SPECT and PET in Imaging Bone Metastases
Seminars in Nuclear Medicine, 10/14/09
Prostate Cancer: Role of SPECT and PET in Imaging Bone Metastases
Seminars in Nuclear Medicine, 10/09/09
Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI
The Journal of Nuclear Medicine, 08/19/09
Sponsor
Article Search
Sponsor